Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Henriksen

Showing results (11-20 of 154) with videos related to

Pageof 16
Sort By:
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|February 7, 2013
Menopause, estrogens and frailtyAnders Nedergaard, Kim Henriksen, Morten Asser Karsdal, et al.
Calcified Tissue International|October 30, 2008
Characterization of the bone phenotype in ClC-7-deficient miceAnita Vibsig Neutzsky-Wulff, Morten A Karsdal, Kim Henriksen
Best Practice & Research. Clinical Obstetrics & Gynaecology|July 30, 2013
Musculoskeletal ageing and primary preventionAnders Nedergaard, Kim Henriksen, Morten A Karsdal, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 17, 2008
Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone qualityMorten A Karsdal, Kim Henriksen, Michel Arnold, et al.
Frontiers in Neurology|May 15, 2025
Exploring Tau-C, Tau-A, and C1M as biomarkers for Parkinson's diseaseMeryem Benmarce, Kim Henriksen, Morten Karsdal, et al.
Journal of Cachexia, Sarcopenia and Muscle|September 22, 2012
Serological muscle loss biomarkers: an overview of current concepts and future possibilitiesAnders Nedergaard, Morten A Karsdal, Shu Sun, et al.
European Journal of Pharmacology|November 22, 2022
Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozinSimone A Melander, Anna Katri, Morten A Karsdal, et al.
Expert Opinion on Therapeutic Targets|May 12, 2015
Novel targets for the prevention of osteoporosis - lessons learned from studies of metabolic bone disordersKim Henriksen, Christian Schneider Thudium, Claus Christiansen, et al.
Plos One|September 11, 2010
The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defectPatrick Schulz, Johannes Werner, Tobias Stauber, et al.
Biomedicines|October 27, 2022
The Impact of Exposure Profile on the Efficacy of Dual Amylin and Calcitonin Receptor Agonist TherapyNina Sonne, Anna Thorsø Larsen, Morten Asser Karsdal, et al.
Pageof 16

Showing results (11-20 of 154) with videos related to

Sort By:
Pageof 16
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|February 7, 2013
Menopause, estrogens and frailtyAnders Nedergaard, Kim Henriksen, Morten Asser Karsdal, et al.
Calcified Tissue International|October 30, 2008
Characterization of the bone phenotype in ClC-7-deficient miceAnita Vibsig Neutzsky-Wulff, Morten A Karsdal, Kim Henriksen
Best Practice & Research. Clinical Obstetrics & Gynaecology|July 30, 2013
Musculoskeletal ageing and primary preventionAnders Nedergaard, Kim Henriksen, Morten A Karsdal, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 17, 2008
Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone qualityMorten A Karsdal, Kim Henriksen, Michel Arnold, et al.
Frontiers in Neurology|May 15, 2025
Exploring Tau-C, Tau-A, and C1M as biomarkers for Parkinson's diseaseMeryem Benmarce, Kim Henriksen, Morten Karsdal, et al.
Journal of Cachexia, Sarcopenia and Muscle|September 22, 2012
Serological muscle loss biomarkers: an overview of current concepts and future possibilitiesAnders Nedergaard, Morten A Karsdal, Shu Sun, et al.
European Journal of Pharmacology|November 22, 2022
Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozinSimone A Melander, Anna Katri, Morten A Karsdal, et al.
Expert Opinion on Therapeutic Targets|May 12, 2015
Novel targets for the prevention of osteoporosis - lessons learned from studies of metabolic bone disordersKim Henriksen, Christian Schneider Thudium, Claus Christiansen, et al.
Plos One|September 11, 2010
The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defectPatrick Schulz, Johannes Werner, Tobias Stauber, et al.
Biomedicines|October 27, 2022
The Impact of Exposure Profile on the Efficacy of Dual Amylin and Calcitonin Receptor Agonist TherapyNina Sonne, Anna Thorsø Larsen, Morten Asser Karsdal, et al.
Pageof 16